hotspot -WSS

hotspot

author：focus 2025-09-29 18:31:23 - browse：332

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： European officials brace for rough respiratory virus season

hotspot

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

Some top drug companies are starting to take action on climate

Health insurers' Q3 question: how much care are people getting?

Heat waves linked to early deliveries, preterm births in new study

Lab trade group sues FDA to halt regulation of lab

IVG is promising — but it won’t replace IVF quite yet

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

The stability of $0 premiums in Medicare Advantage

Apple is now the first public company to be valued at $3 trillion

Stigma and the return of syphilis

Drug repurposing or repositioning? The language matters

Congress extends some pandemic preparedness programs

Supreme Court strikes down use of affirmative action

Adam's Biotech Scorecard: Do Sarepta's exon

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare innovation center doesn’t save money, experts say

explore

Experts study whether long Covid risk adds up with each reinfection

Lab trade group sues FDA to halt regulation of lab

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

The biotech scorecard for Q4: 16 stock

Stop Congress from blocking public access to science

Stigma and the return of syphilis

Wikipedia

explore

hotspot

Wikipedia